Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt(Breast Cancer Now), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Judy E. Garber(Dana-Farber Cancer Institute), Susan M. Domchek(University of Pennsylvania), M. William Audeh(Cedars-Sinai Medical Center), Jeffrey N. Weitzel(City of Hope), Michael Friedländer(Prince of Wales Hospital), Banu Arun(The University of Texas MD Anderson Cancer Center), Niklas Loman(Lund University), Rita K. Schmutzler(University Hospital Cologne), Andrew Wardley(The Christie NHS Foundation Trust), Gillian Mitchell(Peter MacCallum Cancer Centre), Helena Earl(University of Cambridge), Mark Wickens(AstraZeneca (United Kingdom)), James Carmichael(AstraZeneca (United Kingdom))
The Lancet
July 1, 2010
Cited by 1,636

Abstract


Related Papers

No related papers found

Powered by citation graph analysis